UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

Clinical pharmacokinetics, 2014-01, Vol.53 (1), p.1-16

2014

Volltextzugriff (PDF)

The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor

Nature reviews. Drug discovery, 2011-01, Vol.10 (1), p.61-75

2011

Volltextzugriff (PDF)

The effect of food on the absorption and pharmacokinetics of rivaroxaban

International journal of clinical pharmacology and therapeutics, 2013-07, Vol.51 (7), p.549-561

2013

Volltextzugriff (PDF)

The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor

Journal of clinical pharmacology, 2013-03, Vol.53 (3), p.249-255

2013

Volltextzugriff (PDF)

Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects

Journal of clinical pharmacology, 2007-02, Vol.47 (2), p.218-226

2007

Volltextzugriff (PDF)

Rivaroxaban: a new oral factor Xa inhibitor

Arteriosclerosis, thrombosis, and vascular biology, 2010-03, Vol.30 (3), p.376-381

2010

Volltextzugriff (PDF)

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

Current medical research and opinion, 2008-10, Vol.24 (10), p.2757-2765

2008

Volltextzugriff (PDF)

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

British journal of clinical pharmacology, 2010-11, Vol.70 (5), p.703-712

2010

Volltextzugriff (PDF)

Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59-7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

Journal of clinical pharmacology, 2006-05, Vol.46 (5), p.549-558

2006

Volltextzugriff (PDF)

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 : an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects

European journal of clinical pharmacology, 2005-12, Vol.61 (12), p.873-880

2005

Volltextzugriff (PDF)

Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases

Expert opinion on investigational drugs, 2006-08, Vol.15 (8), p.843-855

2006

Volltextzugriff (PDF)

Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications

Clinical and applied thrombosis/hemostasis, 2016-07, Vol.22 (5), p.412-422

2016

Volltextzugriff (PDF)

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study

Thrombosis journal, 2018-12, Vol.16 (1), p.32-12, Article 32

2018

Volltextzugriff (PDF)

Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

British journal of clinical pharmacology, 2013-09, Vol.76 (3), p.455-466

2013

Volltextzugriff (PDF)

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study

Thrombosis journal, 2018-12, Vol.16 (1), p.31-13, Article 31

2018

Volltextzugriff (PDF)

Randomized, Double-Blind, Crossover Study to Investigate the Effect of Rivaroxaban on QT-Interval Prolongation

Drug safety, 2008, Vol.31 (1), p.67-77

2008

Volltextzugriff (PDF)

Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease

CPT: pharmacometrics and systems pharmacology, 2022-08, Vol.11 (8), p.1111-1121

2022

Volltextzugriff (PDF)

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions

CPT: pharmacometrics and systems pharmacology, 2021-10, Vol.10 (10), p.1195-1207

2021

Volltextzugriff (PDF)

Preclinical and Clinical Characteristics of Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor

Seminars in thrombosis and hemostasis, 2007-07, Vol.33 (5), p.515-523

2007

Volltextzugriff (PDF)

Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study

Thrombosis journal, 2018-12, Vol.16 (1), p.34-34, Article 34

2018

Volltextzugriff (PDF)

Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects

British journal of clinical pharmacology, 2009-07, Vol.68 (1), p.77-88

2009

Volltextzugriff (PDF)

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling

CPT: pharmacometrics and systems pharmacology, 2019-11, Vol.8 (11), p.805-814

2019

Volltextzugriff (PDF)

Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects

Clinical pharmacology in drug development, 2013-07, Vol.2 (3), p.270-277

2013

Volltextzugriff (PDF)

Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study

Pharmaceuticals (Basel, Switzerland), 2012-02, Vol.5 (3), p.279-296

2012

Volltextzugriff (PDF)

Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis

Thrombosis journal, 2018-11, Vol.16 (1), p.29-29, Article 29

2018

Volltextzugriff (PDF)

1 – 25 von 84

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(84)

Sprache

Englisch
(84)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor

The effect of food on the absorption and pharmacokinetics of rivaroxaban

The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor

Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects

Rivaroxaban: a new oral factor Xa inhibitor

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59-7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 : an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects

Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases

Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study

Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study

Randomized, Double-Blind, Crossover Study to Investigate the Effect of Rivaroxaban on QT-Interval Prolongation

Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions

Preclinical and Clinical Characteristics of Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor

Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study

Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling

Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects

Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study

Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis

Suchergebnisse filtern